A Study of Flt3-Ligand Levels in Sjögrens Syndrome

Sjogrens Syndrome Clinical Trial

Official title:

Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01470638
• Other study ID #: Flt3-L SS
• Status: Completed
• Start date: June 2009
• Est. completion date: April 2019

Study information

• Verified date: April 2019
• Source: Göteborg University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Description:

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• fulfill the ACR-criteria for primary Sjogrens syndrome,

• age above 18 years old

Exclusion Criteria:

• other CNS-disease

Related Conditions & MeSH terms

• Sjogren's Syndrome
• Sjogrens Syndrome
• Syndrome

Locations

Country	Name	City	State
Sweden	Dept of Rheumatology, Sahlgrenska University Hospital	Gothenburg

Sponsors (1)

Lead Sponsor	Collaborator
Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome		June 2009 - June 2015